Analysis of survival and prognostic differences in locally advanced or metastatic non-squamous non-small cell lung cancer with KRAS mutations
Xiangyu Du, Shanxin Zhang, Yahui Lv, Zhefeng Liu · 2026
Read Analysis of survival and prognostic differences in locally advanced or metastatic non-squamous non-small cell lung cancer with KRAS mutations by Xiangyu Du, Shanxin Zhang, Yahui Lv, Zhefeng Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13266823.txt.
Description
Xiangyu Du and co-authors compare in 2026 first treatments for advanced non-squamous lung cancer carrying a KRAS mutation, using records from a Beijing hospital over a decade. They followed 180 patients whose cancer was locally advanced or had spread. Groups received immune drugs with chemotherapy, either alone, chemotherapy alone, or a triple mix adding a blood vessel blocker.
Immune drugs plus chemotherapy gave the longest control and survival, with responses in about four in ten patients. Adding the vessel blocker brought no clear extra gain. Immune treatment beat chemotherapy alone on survival, while marker levels did not separate who benefited. The authors name the two-drug immune combination as their preferred first choice.
Catalog record
| CREATOR | Xiangyu Du, Shanxin Zhang, Yahui Lv, Zhefeng Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |